Price cuts and the dynamics of the EU market
This article was originally published in Scrip
Executive Summary
The protests against Greek price cuts reported this week are just the latest skirmishes in the unending feud between industry and EU governments over pharmaceutical pricing policies. And disagreements over the extent to which these latest cuts will affect the dynamics of the European pharmaceutical market show how difficult it is to predict the knock-on effects of price changes from one country to another.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.